Elanco Strengthens Board of Directors with Addition of Stacey Ma | PR Newswire [Video]

Ma brings deep manufacturing and innovation expertise

, /PRNewswire/ — Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco’s expertise in these critical areas.

“We are delighted to add Stacey to the Elanco Board,” said Lawrence Kurzius, Chairman of the Elanco Board of Directors. “Her deep understanding of product development, Chemistry, Manufacturing and Controls (CMC) strategy, and technical operations, combined with her proven leadership in driving innovation will be a welcome addition in the board room.”

Dr. Ma currently serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., where she is responsible for product and portfolio strategy, technical development, supply chain, quality, CMC regulatory, and manufacturing operations for Gilead’s small- and large-molecule pipeline. Prior to Gilead, she held leadership positions at Sana Biotechnology, Inc. and Genentech/Roche, including Global Head …